SCHEDULES

SCHEDULE 2Transitionals and savings

Part 15Research and development

Qualifying expenditure on relevant payments to subjects of clinical trials

124

1

In relation to expenditure incurred before 1 August 2008, Chapter 2 of Part 13 (relief for SMEs: cost of R&D borne by SME) applies with the omission of—

a

section 1052(2)(d),

b

section 1071(3)(d),

c

in section 1134(3)(c), the words “or relevant payments to the subjects of a clinical trial”, and

d

section 1140, as it applies for the purposes of that Chapter.

2

In relation to expenditure incurred before 1 August 2008, Chapter 3 of Part 13 (relief for SMEs: cost of R&D sub-contracted to SME) applies with the omission of—

a

section 1066(3)(d), and

b

section 1140, as it applies for the purposes of that Chapter.

3

In relation to expenditure incurred before 1 April 2006, Chapter 4 of Part 13 (relief for SMEs: subsidised expenditure on R&D) applies with the omission of—

a

section 1071(3)(d),

b

in section 1134(3)(c), the words “or relevant payments to the subjects of a clinical trial”, and

c

section 1140, as it applies for the purposes of that Chapter.

4

In relation to expenditure incurred before 1 April 2006, Chapter 5 of Part 13 (relief for large companies) applies with the omission of—

a

section 1077(2)(d), and

b

section 1140, as it applies for the purposes of that Chapter.

5

In relation to expenditure incurred before 1 August 2008, Chapter 7 of Part 13 (relief for SMEs and large companies: vaccine research etc) applies with the omission of—

a

section 1101(4)(d), and

b

section 1140, as it applies for the purposes of that Chapter.